Kidney Week

Abstract: SA-PO769

Optimal Follow-Up Intervals for Different Stages of CKD

Session Information

• CKD: Epidemiology, Risk Factors, Prevention - III
  October 27, 2018 | Location: Exhibit Hall, San Diego Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

• 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

• Hirano, Keita, Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Keita Hirano,

• Ohashi, Yasuo, University of Tokyo, Tokyo, Japan

Yasuo Ohashi,

• Komatsu, Yasuhiro, Gunma University, Graduate School of Medicine, Maebashi, Gunma, Japan

Yasuhiro Komatsu,

• Yanagita, Motoko, Department of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Motoko Yanagita,

• Hishida, Akira, Yaizu City Hospital, Yaizu, Japan

Akira Hishida,

Background

Chronic kidney disease is a public health challenge. However, no evidence-based, optimal, follow-up intervals for patients with chronic kidney disease have been suggested. This study aimed to clarify appropriate follow-up intervals for different chronic kidney disease stages.

Methods

We studied 2682 patients with chronic kidney disease. Both of the numbers of patients experiencing a 50% increase in creatinine and those reaching end-stage renal failure were tabulated by their chronic kidney disease stage. The renal function-testing interval was defined as the estimated time for 0.1% of the patients with chronic kidney disease to have a composite renal outcome, when adjusted for clinical risk factors. Transitions from chronic kidney disease stage-based subgroups were analyzed using parametric cumulative incidence models. Other sensitivity analyses involved the estimation of the time to renal event occurrence for 1% of patients.

Results

Of the 913 patients (34%) who had a composite renal event, 29 patients had stage 3A (10.5%), 151 had stage 3B (16.3%), 429 had stage 4 (41.0%), and 304 had stage 5 chronic kidney disease (70.9%). The estimated renal function testing intervals were 6.0 months for chronic kidney disease stage 3A, 3.4 months for stage 3B, 2.0 months for stage 4, and 1.2 months for stage 5.

Conclusion

The optimal follow-up intervals were longer for patients with lower chronic kidney disease stages. These estimates are longer than those recommended by the relevant guidelines, and may serve as a reference to inform nephrologists in selecting follow-up intervals for their individual patients.